We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
- Authors
Fiebelkorn, Amy Parker; Coleman, Laura A.; Belongia, Edward A.; Freeman, Sandra K.; York, Daphne; Bi, Daoling; Kulkarni, Ashwin; Audet, Susette; Mercader, Sara; McGrew, Marcia; Hickman, Carole J.; Bellini, William J.; Shivakoti, Rupak; Griffin, Diane E.; Beeler, Judith
- Abstract
<bold>Background: </bold>Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective against measles, but waning antibody immunity to measles and failure of the 2-dose vaccine occur. We administered a third MMR dose (MMR3) to young adults and assessed immunogenicity over 1 year.<bold>Methods: </bold>Measles virus (MeV) neutralizing antibody concentrations, cell-mediated immunity (CMI), and immunoglobulin G (IgG) antibody avidity were assessed at baseline and 1 month and 1 year after MMR3 receipt.<bold>Results: </bold>Of 662 subjects at baseline, 1 (0.2%) was seronegative for MeV-neutralizing antibodies (level, <8 mIU/mL), and 23 (3.5%) had low antibody levels (8-120 mIU/mL). One month after MMR3 receipt, 1 subject (0.2%) was seronegative, and 6 (0.9%) had low neutralizing antibodies, with only 21 of 662 (3.2%) showing a ≥ 4-fold rise in neutralizing antibodies. One year after MMR3 receipt, no subject was seronegative, and 10 of 617 (1.6%) had low neutralizing antibody levels. CMI analyses showed low levels of spot-forming cells after stimulation, suggesting the presence of T-cell memory, but the response was minimal after MMR3 receipt. MeV IgG avidity did not correlate with findings of neutralization analyses.<bold>Conclusions: </bold>Most subjects were seropositive before MMR3 receipt, and very few had a secondary immune response after MMR3 receipt. Similarly, CMI and avidity analyses showed minimal qualitative improvements in immune response after MMR3 receipt. We did not find compelling data to support a routine third dose of MMR vaccine.
- Subjects
MEASLES virus; CELLULAR immunity; IMMUNOGLOBULIN G; MUMPS vaccines; RUBELLA vaccines; MEASLES vaccines; VACCINATION; HEALTH of young adults; ANTIGEN-antibody reactions; IMMUNIZATION; IMMUNOGLOBULINS; LONGITUDINAL method; MEDICAL protocols; PARAMYXOVIRUSES; RESEARCH funding; VIRAL antibodies; MMR vaccines; NEUTRALIZATION tests; ODDS ratio
- Publication
Journal of Infectious Diseases, 2016, Vol 213, Issue 7, p1115
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiv555